Zobrazeno 1 - 10 of 120 pro vyhledávání: '"ML de Kam"'
1
Desmopressin as a pharmacological tool in vasopressinergic hypothalamus-pituitary-adrenal axis modulation: Neuroendocrine, cardiovascular and coagulatory effects
Autor: J. Burggraaf, E.G.J. Hulskotte, J.M.A. van Gerven, Pierre A.M. Peeters, J Elassaiss-Schaap, Lineke Zuurman, ML de Kam, Gé S.F. Ruigt, J. van Pelt, Bernard W. M. M. Peeters, Gabriel E. Jacobs
Publikováno v: Journal of Psychopharmacology, 25, 353-60
Journal of Psychopharmacology, 25(3), 353-360
Journal of Psychopharmacology, 25, 3, pp. 353-60
Arginine-vasopressin (AVP) is a physiological co-activator of the hypothalamus–pituitary–adrenal (HPA) axis, together with corticotrophin releasing hormone (CRH). A synthetic analogue of AVP, desmopressin (dDAVP), is often used as a pharmacologic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::974bef2b4785db0ba8c82ddf6cdafab7
https://doi.org/10.1177/0269881109358203
Zobrazit plný text záznamu
2
Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal (HPA) axis: A study in healthy volunteers
Autor: G. Zha, Gabriel E. Jacobs, P. Hu, J. Jiang, J. van Pelt, ML de Kam, J.M.A. van Gerven, Jaap G. Goekoop, Frans G. Zitman, Q. Zhao, E.G.J. Hulskotte
Publikováno v: European Neuropsychopharmacology, 20(12), 866-874
The synthetic vasopressin (AVP) analogue desmopressin (dDAVP) has been used as pharmacological function test to quantify vasopressinergic co-activation of the hypothalamus pituitary adrenal (HPA) axis in the past. Such exogenous vasopressinergic stim
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a0b9d34f016aad0f5e8b12df79fcd233
https://doi.org/10.1016/j.euroneuro.2010.06.009
Zobrazit plný text záznamu
3
A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal axis more integrally in healthy volunteers
Autor: J. van Pelt, Gabriel E. Jacobs, P A M Peeters, J.M.A. van Gerven, Bernard W. M. M. Peeters, Gé S.F. Ruigt, J Elassaiss-Schaap, E.G.J. Hulskotte, ML de Kam
Publikováno v: Journal of Psychopharmacology, 25(3), 361-369
Journal of Psychopharmacology, 25, 361-369
Journal of Psychopharmacology, 25, 3, pp. 361-369
Pharmacological function tests consisting of 100 µg hCRH (corticorelin) and 10 µg dDAVP (desmopressin) mimic endogenous hypothalamus–pituitary–adrenal (HPA) axis activation. However, physiological CRH concentrations preclude informative vasopre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c919822d7542a12f58a6a4d890d27490
https://doi.org/10.1177/0269881109358205
Zobrazit plný text záznamu
4
The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects
Autor: P. De Boer, Remco W. M. Zoethout, Adam F. Cohen, Marieke Liem-Moolenaar, Kari L. Franson, J.M.A. van Gerven, Mark E. Schmidt, ML de Kam
Publikováno v: Journal of Psychopharmacology. 24:1681-1687
The effects of the selective inhibitor of the glycine transporter 1, R231857, in development for schizophrenia, on the central nervous system (CNS) were investigated in healthy males in the absence and presence of scopolamine. This was a double-blind
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55913d73bcd0ae582e370f92892e4890
https://doi.org/10.1177/0269881109105573
Zobrazit plný text záznamu
5
Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron
Autor: Gabriel E. Jacobs, Imc Kamerling, J. van Pelt, Frans G. Zitman, Jma van Gerven, Roel H. DeRijk, ML de Kam
Publikováno v: Journal of Psychopharmacology, 24(1), 65-72
A recently developed oral serotonergic challenge test consisting of 5-Hydroxytryptophane (5-HTP, 200 mg) combined with carbidopa (CBD, 100 mg + 50 mg) exhibited dose-related neuroendocrine responsiveness and predictable pharmacokinetics. However, its
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3483a5e10a324cdfa72ae94e881ae10
https://doi.org/10.1177/0269881108094299
Zobrazit plný text záznamu
6
Pharmacodynamic and pharmacokinetic effects of the intravenously administered CB1 receptor agonist Org 28611 in healthy male volunteers
Autor: Jma van Gerven, Adam F. Cohen, HJ Kleijn, ML de Kam, Pccm Passier, Lineke Zuurman
Publikováno v: Journal of Psychopharmacology. 23:633-644
Abstract CB1/CB2 agonists are reported to have sedative, amnestic, analgesic and anti-emetic properties, which would make them ideal drugs for outpatient treatments under conscious sedation. The main objective of this in human study was to assess the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4889cc0c5d4577a2dbeffddbdd100f20
https://doi.org/10.1177/0269881108091551
Zobrazit plný text záznamu
7
Pharmacodynamics and Pharmacokinetics of the Novel Thrombopoietin Mimetic Peptide RWJ-800088 in Humans
Autor: Adam F. Cohen, CJ Molloy, D Cerneus, Marieke Liem-Moolenaar, KH Brown, J. Burggraaf, D End, ML de Kam, Y van Hensbergen
Publikováno v: Clinical Pharmacology & Therapeutics. 84:481-487
RWJ-800088 is a novel thrombopoietin mimetic peptide for the treatment of thrombocytopenia. The objectives of this study were to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of RWJ-800088 administered as a single int
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::235810444b2a9751e5ced6a49792c762
https://doi.org/10.1038/clpt.2008.96
Zobrazit plný text záznamu
8
Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa
Autor: R.H. de Rijk, J. P. Van Der Post, Gabriel E. Jacobs, Rik C. Schoemaker, J. van Pelt, Dhm Hoeberechts-Lefrandt, Ljca Smarius, ML de Kam, Jma van Gerven, Harm J. Gijsman, Frans G. Zitman
Publikováno v: Journal of Psychopharmacology. 22:426-433
5-hydroxytryptophan (5-HTP) is a direct 5-hydroxytryptamine (5-HT) precursor used to assess central serotonergic function. Its use has been limited by a narrow window between neuroendocrine changes and side effects, and variable kinetics related to i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::898aa52ce437aa8cd14b418ae47669ea
https://doi.org/10.1177/0269881107082025
Zobrazit plný text záznamu
9
The central nervous system effects, pharmacokinetics and safety of the NAALADase-inhibitor GPI 5693
Autor: S. J. De Visser, J.M.A. van Gerven, E. Bortey, M. Woelfler, J. Vornov, E. S. Burak, ML de Kam, B. S. Slusher, Adam F. Cohen, T. Limsakun, D. C. Hilt, J. P. Van Der Post
Publikováno v: British Journal of Clinical Pharmacology. 60:128-136
The aim was to assess the central nervous system (CNS) effects, pharmacokinetics and safety of GPI 5693, an inhibitor of a novel CNS-drug target, NAALADase which is being evaluated for the treatment of neuropathic pain.This was a double-blind, placeb
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29dc817215372a154f0583e49a7c4378
https://doi.org/10.1111/j.1365-2125.2005.02396.x
Zobrazit plný text záznamu
10
No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity
Autor: J.M.A. van Gerven, P. P. de Waal, Adam F. Cohen, ML de Kam, J. P. Van Der Post
Publikováno v: Journal of Psychopharmacology. 18:109-114
This study aimed to evaluate eye blinking as a marker for central dopaminergic activity by investigating the effects of sulpiride (D2-antagonist) and lisuride (D2-agonist) on spontaneous eye blinks. Twelve healthy subjects were included in a randomiz
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5aaad60fb660a4f7f35e49c7cffba674
https://doi.org/10.1177/0269881104042832
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje